Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP)
inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer …

Understanding cancer biology and the development of novel agents for cancer treatment
has always been the goal of cancer researchers. However, the research and development of …

Purpose: The increasing burden of invasive fungal infections results in growing challenges
to antifungal (AF) therapeutic drug monitoring (TDM). This review aims to provide an …

PARP inhibitors have emerged as a promising class of anticancer agents approved for the
treatment of ovarian, breast, prostate, and pancreatic cancer. These inhibitors target PARP …

Abstract P‐glycoprotein (P‐gp) is a transporter protein that is come under the ATP binding
cassette family of proteins. It is situated on the surface of the intestine epithelium, where P …

Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process
and the target of several FDA-approved inhibitors. Several of these inhibitors have been …

Aims Asundexian is an oral, direct and reversible inhibitor of activated factor XI (FXIa) in
development for the treatment of thromboembolic events. This article summarizes results …

Abstract Itraconazole (ITC), a well-tolerated antifungal drug, exerts multiple anticancer
effects which justified its preclinical and clinical investigation as potential anti-cancer agent …

Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP)
inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has …

ABSTRACT Introduction BRCA1 and BRCA2 (BRCA1/2) mutation breast cancers constitute
an uncommon, but unique group of breast cancers that present at a younger age, and are …